Accelerating PROTAC drug discovery: Establishing a Relationship Between Ubiquitination and Target Protein Degradation
MALVERN, Pa., SEP 1, 2022 – LifeSensors Inc., a Biotech and Drug Discovery Company focused on PROTAC, molecular glues, and neurodegeneration diagnostics, is pleased to announce that Lifesensors has published a seminal paper: Accelerating PROTAC drug discovery: Establishing a relationship between ubiquitination and target protein degradation. This paper is published in the Biochemical and Biophysical […]